Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban

Abstract

Patients with atrial fibrillation and prior stroke or transient ischemic attack exhibit a very high risk of recurrence. Secondary prevention with oral anticoagulants is mandatory. Overall, clinical guidelines recommend the use of target-specific oral anticoagulants over vitamin K antagonists for secondary prevention of stroke in patients with atrial fibrillation. However, many patients with atrial fibrillation and previous stroke are not receiving the appropriate antithrombotic treatment, perhaps due to the perceived risks of anticoagulation including the risk of hemorrhagic transformation of an ischemic stroke. The ENGAGE AF-TIMI 48 trial showed that although edoxaban 60 mg and warfarin reduced the risk of stroke to a similar extent, edoxaban exhibited a lesser risk of bleeding, particularly intracranial hemorrhage. Importantly, these data were independent of the presence of prior stroke or transient ischemic attack. Therefore, edoxaban can be used in both primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation. The aim of this review was to update the available evidence about edoxaban in the clinical management of secondary prevention in individuals with non-valvular atrial fibrillation.

KEYWORDS:

• anticoagulation
• atrial fibrillation
• edoxaban
• ENGAGE AF-TIMI 48
• secondary prevention

Acknowledgements

Editorial assistance was provided by Content Ed Net, Madrid, Spain.

Declaration of Interest

No potential conflict of interest was reported by the authors. Jaime Masjuan has participated in advisory boards and lectures for Daiichi Sankyo, Bayer, Boehringer Ingelheim, Pfizer and Bristol-Myers Squibb.